Could Nafamostat or Gabexate Prevent the Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis? | Zendy

Yong Hwan Kwon | Zendy; Jiyeon Kim | Zendy; Sang Jik Lee | Zendy; Se Young Jang | Zendy; Hyun Woo Park | Zendy; Hae Min Yang | Zendy; Min Kyu Jung | Zendy; Seong Woo Jeon | Zendy; Chang Min Cho | Zendy; Won Young Tak | Zendy; Young Oh Kweon | Zendy; Sung Kook Kim | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Could Nafamostat or Gabexate Prevent the Post Endoscopic Retrograde Cholangiopancreatography Pancreatitis?

Author(s) -

Yong Hwan Kwon,

Jiyeon Kim,

Sang Jik Lee,

Se Young Jang,

Hyun Woo Park,

Hae Min Yang,

Min Kyu Jung,

Seong Woo Jeon,

Chang Min Cho,

Won Young Tak,

Young Oh Kweon,

Sung Kook Kim

Publication year - 2012

Publication title -

korean journal of gastroenterology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.203

H-Index - 25

eISSN - 2233-6869

pISSN - 1598-9992

DOI - 10.4166/kjg.2012.59.3.232

Subject(s) - medicine , endoscopic retrograde cholangiopancreatography , pancreatitis , placebo , incidence (geometry) , gastroenterology , placebo group , surgery , pathology , physics , alternative medicine , optics

ERCP is the most common procedure for the diagnosis and treatment of bile duct and pancreatic disease, but Post-ERCP pancreatitis makes poor outcome in some cases. The protease inhibitors, nafamostat and gabexate, have been used to prevent pancreatitis related to ERCP, but there is some debate. We tried to evaluate the efficacy of gabexate and nafamostat for the prevention of post-ERCP pancreatitis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research